Iterum Therapeutics Provides Business Update
Iterum Therapeutics provided a business update. Market Access Update: Medicare Part D Milestone: The company announces another signed rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers. This agreement positions Orlynvah for inclusion on their Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies. Patent Portfolio: Iterum has been granted a patent in the United States as patent number 12,544,337, entitled "Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof", that covers a bilayer tablet comprising sulopenem etzadroxil and probenecid, a method of making the bilayer tablet, and methods of treating diseases, including uncomplicated urinary tract infection. This US patent is projected to expire in December 2039, absent any patent term extensions, and assuming timely payments of all maintenance fees during the lifetime of the patent. FDA: The US Food and Drug Administration has responded to Iterum's request to discuss the use of Orlynvah as step-down therapy and the collection of real world data to support the proposed claim. The FDA has determined that Iterum would need to provide substantial evidence of effectiveness from an adequate and well-designed clinical trial in a supplemental new drug application to support the proposed indication for Orlynvah as step-down treatment of complicated urinary tract infections. The FDA recommends that Iterum request a Type C meeting to discuss the design and endpoints of any proposed clinical investigation to support the proposed indication.
Trade with 70% Backtested Accuracy
Analyst Views on ITRM
About ITRM
About the author
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
- FDA Recommendation: The FDA has recommended a type C meeting for a proposed clinical investigation related to Orlyn NVH.
- Purpose of Meeting: The meeting aims to discuss the clinical development plan and address any questions regarding the proposed investigation.
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
- Expanded Coverage: ORLYNVAH™ now reaches nearly 25% of insured lives in the U.S., with increasing integration into employer groups and payer formularies, which is expected to enhance market penetration significantly.
- Pharmacy Benefit Agreement: Iterum has signed a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in their formularies starting Q1 2026, which will greatly improve product accessibility in the market.
- Increased Distribution Channels: ORLYNVAH™ is now stocked at additional distributors like Cencora, allowing physicians to procure the product through various channels, thereby enhancing market availability and procurement flexibility for doctors.
- Patent Expansion: The European Patent Office has indicated its intention to grant a patent covering a bilayer tablet of sulopenem etzadroxil and probenecid, projected to expire in December 2039, which strengthens Iterum's intellectual property protection in the anti-infective space.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
ITERUM THERAPEUTICS PLC: FDA Suggests Type C Meeting for Proposed Clinical Study of ORLYNVAH
- FDA Recommendation: The FDA has recommended a type C meeting for a proposed clinical investigation related to Orlyn NVH.
- Purpose of Meeting: The meeting aims to discuss the clinical development plan and address any questions regarding the proposed investigation.
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.
- Expanded Coverage: ORLYNVAH™ now reaches nearly 25% of insured lives in the U.S., with increasing integration into employer groups and payer formularies, which is expected to enhance market penetration significantly.
- Pharmacy Benefit Agreement: Iterum has signed a rebate agreement with a top Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in their formularies starting Q1 2026, which will greatly improve product accessibility in the market.
- Increased Distribution Channels: ORLYNVAH™ is now stocked at additional distributors like Cencora, allowing physicians to procure the product through various channels, thereby enhancing market availability and procurement flexibility for doctors.
- Patent Expansion: The European Patent Office has indicated its intention to grant a patent covering a bilayer tablet of sulopenem etzadroxil and probenecid, projected to expire in December 2039, which strengthens Iterum's intellectual property protection in the anti-infective space.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
